Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study

References

• Ghosn J, Taiwo B, Seedat S, et al. HIV. Lancet. 2018 Aug 25;392(10148):685–697. doi:10.1016/s0140-6736(18)31311-4.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gorden F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. doi:10.1056/NEJMoa1506816.
   PubMed Web of Science ®Google Scholar
• Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis. 2007;195(3):425–431. doi:10.1086/510536.
   PubMed Web of Science ®Google Scholar
• Nsanzimana S, Remera E, Kanters S, et al. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study. Lancet HIV. 2015;2(9):e376–e384. doi:10.1016/s2352-3018(15)00112-5.
   PubMed Web of Science ®Google Scholar
• Trickey A, May MT, Schommers P, et al. CD4:CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the antiretroviral therapy cohort Collaboration (ART-CC). Clin Infect Dis. 2017;65(6):959–966. doi:10.1093/cid/cix466.
   PubMed Web of Science ®Google Scholar
• Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar;2(3):e98–106. doi:10.1016/s2352-3018(15)00006-5.
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078. doi:10.1371/journal.ppat.1004078.
   PubMed Web of Science ®Google Scholar
• Ma Y, Dou Z, Guo W, et al. The Human immunodeficiency virus care Continuum in China: 1985-2015. Clin Infect Dis. 2018 Mar 5;66(6):833–839. doi:10.1093/cid/cix911.
   PubMed Web of Science ®Google Scholar
• Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr. 2013;63(5):e150–e157. doi:10.1097/QAI.0b013e3182948d82.
   PubMed Web of Science ®Google Scholar
• Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National free antiretroviral treatment Program. Ann Intern Med. 2009;151(4):241–251. doi:10.7326/0003-4819-151-4-200908180-00006.
   PubMed Web of Science ®Google Scholar
• Chen M, Dou Z, Wang L, et al. Gender differences in outcomes of antiretroviral treatment among HIV-infected patients in China: a retrospective cohort study, 2010-2015. J Acquir Immune Defic Syndr. 2017;76(3):281–288. doi:10.1097/qai.0000000000001500.
   PubMed Web of Science ®Google Scholar
• Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008;47(6):825–833. doi:10.1086/590945.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang F, Zhao Y, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol. 2010;39(4):973–979. doi:10.1093/ije/dyp233.
   PubMed Web of Science ®Google Scholar
• Chinese Center for Disease Control and Prevention. China free ART manual. Beijing: Ministry of Health; 2005.
   Google Scholar
• Qiu P, Sheng J. A two-stage procedure for comparing hazard rate functions. J R Stat Soc Series B Stat Methodol. 2008;70(1):191–208. doi:10.1111/j.1467-9868.2007.00622.x.
   Google Scholar
• Zhang F, Zhu H, Wu Y, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National free antiretroviral treatment Program, 2010–12: a retrospective observational cohort study. Lancet Infect Dis. 2014;14 (11):1065–1072. doi:10.1016/S1473-3099(14)70946-6.
   PubMed Web of Science ®Google Scholar
• Weimin J, Pan X, Kang L, et al. Comparision between values of CD4, CD8, CD4/CD8 among HIV infectors and normal adults in Shanghai. China J AIDS/STD. 2002;8(2):71–73.
   Google Scholar
• Liu S, Liu W, Chen J. Analysis of T lymphocyte subsets in normal healthy Chinese adults in the Guangxi Zhuang Autonomous Region. China J AIDS/STD. 2004;6(10):413–415.
   Google Scholar
• Jian-Mei HE, Zou XB, Peng JY, et al. Normal reference values of peripheral blood CD3+,CD4+ and CD8+ T lymphocytes in healthy Miao ethnics in Hunan province. Chin J Infect Control. 2009;8(002):82–85.
   Google Scholar
• Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ t cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004 Sep 20;200(6):749–759. doi:10.1084/jem.20040874.
   PubMed Web of Science ®Google Scholar
• Ferrando-Martinez S, De Pablo-Bernal RS, De Luna-Romero M, et al. Thymic function failure is associated with human immunodeficiency virus disease progression. Clin Infect Dis. 2017 May 1;64(9):1191–1197. doi:10.1093/cid/cix095.
   PubMed Web of Science ®Google Scholar
• Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010 May 1;50(9):1300–1308. doi:10.1086/651689.
   PubMed Web of Science ®Google Scholar
• Rb-Silva R, Nobrega C, Azevedo C, et al. Thymic function as a predictor of immune recovery in Chronically HIV-infected patients initiating antiretroviral therapy. Front Immunol. 2019;10:25. doi:10.3389/fimmu.2019.00025.
   PubMed Web of Science ®Google Scholar
• Shenoy MK, Fadrosh DW, Lin DL, et al. Gut microbiota in HIV-pneumonia patients is related to peripheral CD4 counts, lung microbiota, and in vitro macrophage dysfunction. Microbiome. 2019 Mar 11;7(1):37. doi:10.1186/s40168-019-0651-4.
   PubMed Web of Science ®Google Scholar
• Warren JA, Clutton G, Goonetilleke N. Harnessing CD8 T cells under HIV antiretroviral therapy. Front Immunol. 2019;10:291. doi:10.3389/fimmu.2019.00291.
   PubMed Web of Science ®Google Scholar
• Cao W, Mehraj V, Kaufmann D E, et al. Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J Int AIDS Soc. 2016;19(1):20697. doi:10.7448/ias.19.1.20697.
   PubMed Web of Science ®Google Scholar
• Sainz T, Serrano-Villar S, Diaz L, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS. 2013;27(9):1513–1516. doi:10.1097/QAD.0b013e32835faa72.
   PubMed Web of Science ®Google Scholar
• Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014 May;58(9):1312–1321. doi:10.1093/cid/ciu038.
   PubMed Web of Science ®Google Scholar
• Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9(3):e1001194. doi:10.1371/journal.pmed.1001194.
   PubMed Web of Science ®Google Scholar
• Roul H, Mary-Krause M, Ghosn J, et al. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. AIDS. 2018 Nov 13;32(17):2605–2614. doi:10.1097/qad.0000000000002010.
   PubMed Web of Science ®Google Scholar
• Tanuma J, Matsumoto S, Haneuse S, et al. Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam. J Int AIDS Soc Society. 2017;20(4). doi:10.1002/jia2.25030.
   Google Scholar
• Okulicz JF, Le TD, Agan BK, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med. 2015 Jan;175(1):88–99. doi:10.1001/jamainternmed.2014.4010.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. Br Med J. 2009;338:a3172. doi:10.1136/bmj.a3172.
   PubMed Web of Science ®Google Scholar
• Lee SS, Wong NS, Wong BCK, et al. Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: an observational cohort study. BMJ Open. 2017;7(9):e016886. doi:10.1136/bmjopen-2017-016886.
   PubMed Web of Science ®Google Scholar
• Gabillard D, Lewden C, Ndoye I, et al. Mortality, AIDS-morbidity and loss to follow-up by current CD4 cell count among HIV-1 infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr. 2013;62(5):555. doi:10.1097/QAI.0b013e3182821821.
   PubMed Web of Science ®Google Scholar
• Demontès M, Allavena C, Jovelin T, et al. Multimorbidity in elderly subjects according to the year of diagnosis of HIV-infection-A Cross-Sectional DATAIDS cohort study. Clin Infect Dis. 2019. doi:10.1093/cid/ciz1171.
   Web of Science ®Google Scholar
• Menozzi M, Zona S, Santoro A, et al. CD4/CD8 ratio is not predictive of multi-morbidity prevalence in HIV-infected patients but identify patients with higher CVD risk. J Int AIDS Soc. 2014;17(4 Suppl 3):19709. doi:10.7448/IAS.17.4.19709.
   PubMed Web of Science ®Google Scholar